Site icon pharmaceutical daily

Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States

(Illustration) Teva USA. Image source: Tevapharm

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced the launch of a generic version of VESIcare ®1
(solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.

Solifenacin Succinate Tablets are a muscarinic antagonist indicated for
the treatment of overactive bladder with symptoms of urge urinary
incontinence, urgency, and urinary frequency. Overactive bladder (OAB)
is most often characterized by a strong sudden urge to urinate that is
difficult to control.

“About 33 million Americans have overactive bladder.2 We’re
proud to offer another treatment option for this common condition,” said
Brendan O’Grady, EVP and Head of North America Commercial.

With nearly 500 generic medicines available, Teva has the largest
portfolio of FDA-approved generic products on the market and holds the
leading position in first-to-file opportunities, with over 100 pending
first-to-files in the U.S. Currently, one in eight generic prescriptions
dispensed in the U.S. is filled with a Teva generic product.

VESIcare® Tablets have annual sales of more than $955 million
in the U.S., according to IQVIA data as of February 2019.

About Solifenacin Succinate Tablets

Solifenacin Succinate Tablets are a muscarinic antagonist indicated for
the treatment of overactive bladder with symptoms of urge urinary
incontinence, urgency, and urinary frequency.

IMPORTANT SAFETY INFORMATION

Solifenacin Succinate Tablets are contraindicated in patients with
urinary retention, gastric retention, uncontrolled narrow-angle
glaucoma, and in patients who have demonstrated hypersensitivity to the
drug.

Angioedema of the face, lips, tongue, and/or larynx have been reported
with solifenacin. Angioedema associated with upper airway swelling may
be life threatening. Anaphylactic reactions have been reported rarely in
patients treated with solifenacin succinate. Solifenacin Succinate
Tablets should not be used in patients with a known or suspected
hypersensitivity to solifenacin succinate.

Solifenacin succinate should be administered with caution to patients
with clinically significant bladder outflow obstruction because of the
risk of urinary retention. Solifenacin succinate should be used with
caution in patients with decreased gastrointestinal motility.
Solifenacin succinate is associated with anticholinergic central nervous
system (CNS) effects. A variety of CNS anticholinergic effects have been
reported, including headache, confusion, hallucinations and somnolence.
Solifenacin succinate should be used with caution in patients being
treated for narrow-angle glaucoma.

Solifenacin succinate should be used with caution in patients with
hepatic or renal impairment. Doses of solifenacin succinate greater than
5 mg are not recommended in patients with moderate hepatic impairment or
severe renal impairment. Solifenacin succinate is not recommended for
patients with severe hepatic impairment. Solifenacin succinate should be
used with caution in patients with a known history of QT prolongation or
patients who are taking medications known to prolong the QT interval.

In clinical trials, the most common adverse reactions (> 4% and >
placebo) were dry mouth, and constipation at both 5 mg and 10 mg doses;
and urinary tract infection, and blurred vision at the 10 mg dose.

For more information, please see accompanying Full
Prescribing Information
. A copy may be requested from Teva U.S.
Medical Information at 888-TEVA-USA (888-838-2872), druginfo@tevapharm.com,
or Teva’s Public Relations or Investor Relations contacts.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been
developing and producing medicines to improve people’s lives for more
than a century. We are a global leader in generic and specialty
medicines with a portfolio consisting of over 35,000 products in nearly
every therapeutic area. Around 200 million people around the world take
a Teva medicine every day, and are served by one of the largest and most
complex supply chains in the pharmaceutical industry. Along with our
established presence in generics, we have significant innovative
research and operations supporting our growing portfolio of specialty
and biopharmaceutical products. Learn more at www.tevapharm.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
regarding the launch and potential benefits of the generic version of
VESIcare®,
which are based on management’s current beliefs and expectations and are
subject to substantial risks and uncertainties, both known and unknown,
that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to:

and other factors discussed in our Annual Report on Form 10-K for the
year ended December 31, 2018, including the sections thereof captioned
“Risk Factors.” Forward-looking statements speak only as of the date on
which they are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information.

1 VESIcare® is a registered trademark of Astellas
Pharma, Inc.
2 Urology Care Foundation: https://www.urologyhealth.org/urologic-conditions/overactive-bladder-(oab)

Contacts

IR
United States
Kevin C. Mannix
(215)
591-8912

Israel
Ran Meir
972 (3) 926-7516

PR
United
States

Kelley Dougherty
(973) 658-0237

Israel
Yonatan
Beker
972 (54) 888 5898

Exit mobile version